StockData
QIAGEN N.V. logo

QIAGEN N.V. (QGEN) stock

QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 10/30
$49.75−0.06 (-0.12%)

Close on Nov 17, 2026Market cap $10.79BP/E 25.6Yield 0.50%

Qiagen r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $187.52M, down 3.1% from the year before. Over ten years it grew 2.5% a year on average. The highest annual figure on record is $198.51M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$187.52M-3.1%
FY2024Dec 31, 2024$193.49M-2.5%
FY2023Dec 31, 2023$198.51M+4.6%
FY2022Dec 31, 2022$189.86M-0.1%
FY2021Dec 31, 2021$189.96M+27.4%
FY2020Dec 31, 2020$149.07M-5.3%
FY2019Dec 31, 2019$157.45M-2.7%
FY2018Dec 31, 2018$161.85M+5.0%
FY2017Dec 31, 2017$154.08M+2.8%
FY2016Dec 31, 2016$149.84M+2.1%
FY2015Dec 31, 2015$146.83M-10.3%
FY2014Dec 31, 2014$163.67M+12.0%
FY2013Dec 31, 2013$146.07M+19.3%
FY2012Dec 31, 2012$122.48M-6.2%
FY2011Dec 31, 2011$130.64M+3.6%
FY2010Dec 31, 2010$126.04M+16.8%
FY2009Dec 31, 2009$107.90M+10.9%
FY2008Dec 31, 2008$97.33M–

More Qiagen figures

See a number that looks wrong?